💨 Abstract
Syngene International, an Indian contract research firm, has acquired a biologics facility in the US from Emergent BioSolutions for $36.5 million. The facility is strategically located near key biotech hubs in the Northeast U.S., and is expected to be operational for client projects from the second half of 2025.
Courtesy: theprint.in
Summarized by Einstein Beta 🤖
Suggested
Prince Frederik of Luxembourg dies at 22 due to genetic disorder
India, Armenia looking at boosting cooperation in trade, connectivity
283 Indians, lured into illegal jobs in Myanmar, rescued
PM Modi leaves for Mauritius on 2-day visit
Exclusive-CoreWeave wins $12 billion cloud contract from OpenAI ahead of IPO, sources say
PM Modi to inaugurate over 20 India-funded projects in Mauritius
Soccer-Feyenoord coach Van Persie still hoping to get past Inter
Apple preparing for a major software overhaul, Bloomberg News reports
Solong and Stena both sustained significant damage in shipping collision, container owner says
Oil settles down 1.5% as tariffs prompt fears of slow demand
Powered by MessengerX.io